Spots Global Cancer Trial Database for AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme

Official Title: A Phase II Study of AZD2171 in Recurrent Glioblastoma

Study ID: NCT00305656

Conditions

Adult Giant Cell Glioblastoma

Adult Glioblastoma

Adult Gliosarcoma

Recurrent Adult Brain Tumor

Interventions

cediranib maleate

Study Description

Brief Summary: This phase II trial is studying how well AZD2171 works in treating patients with recurrent glioblastoma multiforme. AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor

Detailed Description: PRIMARY OBJECTIVE: I. Determine the proportion of patients with recurrent glioblastoma multiforme (GM) who are alive and progression free 6 months after starting AZD2171 therapy. SECONDARY OBJECTIVES: I. Assess the biological effect of AZD2171 by using the following MRI techniques: dynamic contrast-enhanced imaging; arterial spin-labeling imaging; perfusion-weighted imaging; and diffusion- tensor imaging at serial time points. II. Measure circulating endothelial and progenitor cells and plasma levels of tumstatin, (vascular endothelial growth factor (VEGF)-A and -D, sVEGF receptors, P1GF, platelet-derived growth factor (PDGF)-AA, PDGF-AB, PDGF-BB, Ang1, thrombospondin-1, and interleukin-8 as markers for response to antiangiogenic therapy in recurrent GM. III. Correlate treatment outcomes with pre-AZD2171 tumor specimens with respect to microvascular density, basement membrane and pericyte coverage, and angiopoietin-1 and -2 expression to determine whether these immunohistochemical analyses can be predictive of the response to AZD2171. IV. Measure polymorphisms of kdr/flk-1 gene and genetic analysis of HIF1-alpha, TP53, and endothelial nitric oxide synthase genes in the archival tumor specimens. V. Determine the overall survival of patients with recurrent GM treated with AZD2171. VI. Determine the radiographic response rate in patients with recurrent GM treated with AZD2171. VII. Determine the safety of AZD2171 in this patient population. OUTLINE: This is a multicenter study. Patients receive oral AZD2171 once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed periodically for up to 12 months.